BRD4 and hepatocellular carcinoma: A recent meta-analysis on 17 randomized-controlled trials observed that mutations of TERT, CTNNB1, BRD4, or MLL, and co-mutations in TP53/TERT and TP53/BRD4, were associated with worse survival, and a risk score based on these mutations may be more predictive for survival of ICI-treated HCC patients than TMB [127].